--- title: "Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 7.6% - Should You Sell?" description: "Cullinan Therapeutics (NASDAQ:CGEM) shares fell 7.6% to $11.95, with trading volume up 84%. Analysts have mixed ratings: Wedbush and HC Wainwright issued 'buy' ratings with target prices of $25 and $2" type: "news" locale: "en" url: "https://longbridge.com/en/news/267572708.md" published_at: "2025-11-26T18:05:12.000Z" --- # Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 7.6% - Should You Sell? > Cullinan Therapeutics (NASDAQ:CGEM) shares fell 7.6% to $11.95, with trading volume up 84%. Analysts have mixed ratings: Wedbush and HC Wainwright issued 'buy' ratings with target prices of $25 and $26, respectively, while Weiss Ratings gave a 'sell' rating. The stock has a consensus 'Moderate Buy' rating with a $27 target price. Insider and hedge fund activities show increased interest, with insiders owning 7.16% and institutional investors holding 86.31% of shares. Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) traded down 7.6% during trading on Tuesday . The company traded as low as $11.43 and last traded at $11.95. 1,110,178 shares traded hands during mid-day trading, an increase of 84% from the average session volume of 602,640 shares. The stock had previously closed at $12.93. Get **Cullinan Therapeutics** alerts: ## Wall Street Analysts Forecast Growth CGEM has been the topic of several research reports. Wedbush reaffirmed an "outperform" rating and issued a $25.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, November 20th. Weiss Ratings reissued a "sell (e+)" rating on shares of Cullinan Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley dropped their price objective on Cullinan Therapeutics from $35.00 to $28.00 and set an "overweight" rating on the stock in a report on Monday, August 18th. HC Wainwright raised their price objective on shares of Cullinan Therapeutics from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Thursday, November 20th. Finally, New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.00. **View Our Latest Report on Cullinan Therapeutics** ## Cullinan Therapeutics Trading Down 10.5% The stock has a market capitalization of $683.51 million, a price-to-earnings ratio of -3.50 and a beta of -0.07. The company has a fifty day moving average of $7.47 and a two-hundred day moving average of $7.69. Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.18. As a group, sell-side analysts predict that Cullinan Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year. ## Insider Transactions at Cullinan Therapeutics In related news, major shareholder Lynx1 Capital Management Lp acquired 165,667 shares of the business's stock in a transaction dated Tuesday, October 28th. The stock was acquired at an average price of $8.40 per share, with a total value of $1,391,602.80. Following the completion of the transaction, the insider owned 8,963,500 shares of the company's stock, valued at approximately $75,293,400. This represents a 1.88% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 1,874,057 shares of company stock valued at $13,325,286. Company insiders own 7.16% of the company's stock. ## Hedge Funds Weigh In On Cullinan Therapeutics A number of hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group acquired a new stake in shares of Cullinan Therapeutics during the 1st quarter valued at about $34,000. SG Americas Securities LLC acquired a new position in Cullinan Therapeutics in the third quarter worth about $62,000. Tower Research Capital LLC TRC lifted its stake in Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock worth $62,000 after purchasing an additional 2,523 shares during the period. Inscription Capital LLC acquired a new stake in Cullinan Therapeutics during the third quarter valued at approximately $67,000. Finally, Compass Ion Advisors LLC bought a new stake in shares of Cullinan Therapeutics in the 3rd quarter valued at approximately $82,000. Institutional investors and hedge funds own 86.31% of the company's stock. ## Cullinan Therapeutics Company Profile (Get Free Report) Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. ## Featured Articles - Five stocks we like better than Cullinan Therapeutics - What Are Earnings Reports? - A New Leader at Six Flags: Is the Roller Coaster Over? - Canadian Penny Stocks: Can They Make You Rich? - 3 Reasons Baidu Could Be the Dark Horse of Global AI - What is Short Interest? How to Use It - Betting on the Backbone: 3 AI Infrastructure Stocks *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Cullinan Therapeutics Right Now? Before you consider Cullinan Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list. While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CGEM.US - Cullinan Therapeutics](https://longbridge.com/en/quote/CGEM.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 內部人士出售：Cullinan Therapeutics（納斯達克股票代碼：CGEM）的內部人士出售了 3,601 股股票 | Cullinan Therapeutics 的內部人士 Jacquelyn Sumer 出售了 3,601 股，價格為每股 14.47 美元，總計 52,106.47 美元，代表其持股減少了 2.73%。交易後，她持有 128,089 股， | [Link](https://longbridge.com/en/news/276951436.md) | | Cullinan Therapeutics 宣稱 2026 年將是 “關鍵的一年”，因為 T 細胞參與者和 Zipalertinib 催化劑即將到來 | Cullinan Therapeutics（納斯達克代碼：CGEM）高管宣佈，2026 年將是公司 “決定性的一年”，在花旗集團的虛擬腫瘤領導峯會上強調了其腫瘤學和自身免疫組合中多個即將到來的催化劑。首席執行官 Nadim Ahmed 和首 | [Link](https://longbridge.com/en/news/276398592.md) | | 內幕交易：Maplight Therapeutics（NASDAQ:MPLT）的一位董事出售了 11,264 股股票 | Maplight Therapeutics 的董事 Robert Malenka 以每股 18.42 美元的價格出售了 11,264 股，總計 207,482.88 美元，代表其持股減少了 3.34%。出售後，他持有 325,795 股，價 | [Link](https://longbridge.com/en/news/276805233.md) | | Cullinan Therapeutics 通過第二季度的 CLN-978 數據和 AML 快速通道的勢頭，為催化劑密集的 2026 年做好準備 | Cullinan Therapeutics（納斯達克股票代碼：CGEM）預計 2026 年將迎來多個催化劑，重點關注兩個針對自身免疫疾病和急性髓系白血病（AML）的關鍵 T 細胞結合劑項目。首席執行官 Nadim Ahmed 強調公司財務狀 | [Link](https://longbridge.com/en/news/275861806.md) | | Cullinan Therapeutics 的高管將參加 Guggenheim Emerging Outlook Biotech Summit | Cullinan Therapeutics Inc. 將於 2026 年 2 月 12 日上午 11:00（東部時間）參加在古根海姆舉辦的 “新興前景：生物技術峯會 2026” 的爐邊談話。首席執行官 Nadim Ahmed 和首席醫學官 | [Link](https://longbridge.com/en/news/274967330.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.